Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Study type
- Clinical guideline
- Study name
- ESMO MZL 2020
- Design
- Clinical guideline (ESMO Clinical Practice Guidelines)
- Source
- Annals of Oncology · 2020
In plain words
This article is a clinical guideline from the European Society for Medical Oncology (ESMO). Its subject is how to diagnose, treat and follow up a group of lymphomas called marginal zone lymphomas. Doctors use this guideline to make decisions about patient care. The treatment decision for each patient should be made by the treating doctor according to that patient's situation.
Clinical significance and place in guidelines
From the PubMed record it can only be said that this guideline was published in 2020 by the ESMO Guidelines Committee on the diagnosis, treatment and follow-up of marginal zone lymphomas. Its recommendations are not given in the record. To assess its clinical impact and the current status of the guideline, the full text should be reviewed. The record refers to an erratum in Ann Oncol 2023;34(3):325, which should be reviewed together with the original text.
Limitations
The PubMed record does not contain an abstract or the text of the recommendations, so levels of evidence and grades of recommendation are not included in this card. To review the recommendations, the full text of the guideline and the 2024 erratum should be checked.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.